Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Peer reviewedOpen accessAIDS

Cotrimoxazole Prophylaxis Increases Resistance Gene Prevalence and α-Diversity but Decreases β-Diversity in the Gut Microbiome of Human Immunodeficiency Virus–Exposed, Uninfected Infants

Clinical Infectious Diseases·

Alaric W D’Souza, Eshia Moodley-Govender, Bertram Berla, Tejas Kelkar, Bin Wang, Xiaoqing Sun, Brodie Daniels, Anna Coutsoudis, Indi Trehan, Gautam Dantas

DOI
10.1093/cid/ciz1186
PMID
31832638
PMCID
PMC7778358
OpenAlex
W2994920208
Study type
Guideline
Publisher
Oxford University Press (OUP)
Article type
journal-article
Integrity
current

Why this research matters now

Rising antibiotic resistance poses particular concern in low- and middle-income countries with higher perinatal HIV exposure rates and wider cotrimoxazole prophylaxis use. Findings may inform revisions to current infant prophylaxis guidelines.

01

Structured evidence summary

Research question

The study examined how prophylactic cotrimoxazole treatment affects the gut microbiome and antibiotic resistance genes in HIV-exposed, uninfected infants.

Study design

Randomized trial with whole-metagenome sequencing of 163 stool samples collected longitudinally from 63 HIV-exposed, uninfected infants assigned to receive (n=34) or not receive (n=29) cotrimoxazole prophylaxis.

Population and setting

HIV-exposed, uninfected infants randomized to cotrimoxazole prophylaxis (n=34) or no prophylaxis (n=29), with samples collected over at least six months.

Main findings

Cotrimoxazole prophylaxis did not alter taxonomic or functional pathway diversity but significantly increased antibiotic resistance gene prevalence and within-sample diversity, with effects strengthening over time. Between-sample diversity decreased for taxonomy, functional pathways, and resistance genes in treated infants, consistent with antibiotic selection pressure.

Public-health relevance

Rising antibiotic resistance poses particular concern in low- and middle-income countries with higher perinatal HIV exposure rates and wider cotrimoxazole prophylaxis use. Findings may inform revisions to current infant prophylaxis guidelines.

Important limitations

This summary is limited to the supplied single-article abstract and metadata. Full interpretation of microbiome changes, clinical significance, and generalizability requires access to the complete published article.

GIDS interpretation

The article was classified under AIDS, antimicrobial resistance, health policy, and treatment topics. It addresses a guideline-related intervention (cotrimoxazole prophylaxis in HIV-exposed infants) and contributes evidence on unintended microbiome and resistance outcomes that may inform policy refinement.

02

Related GIDS surveillance

Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.

03

Evidence relationships

This article has 12 auditable classifier relationships to diseases, places, topics, and study design.

about diseaseaddresses topicaddresses topicaddresses topicevaluates interventionhas pathogen typeinforms policy domainstudied population settingstudies pathogenstudies populationstudies populationuses study design